Lower Risk of Infectious Deaths in Cardiac Transplant Patients Receiving Basiliximab Versus Anti-thymocyte Globulin as Induction Therapy

Journal of Heart and Lung Transplantation

Volumn 26, Issue 7, 2007, Pages 693-699

  Mattei, Marie Françoise ^a   Redonnet, Michel ^b   Gandjbakhch, Iradj ^c   Bandini, Annick Mouly ^d   Billes, Allain ^e   Epailly, Eric ^f   Guillemain, Romain ^g   Lelong, Bernard ^h   Pol, Annie ⁱ   Treilhaud, Michelle ^j   Vermes, Emmanuelle ^k   Dorent, Richard ^l   Lemay, Djamila ^m   Blanc, Anne Sandrine ^m   Boissonnat, Pascale ⁿ  

^a CHU NANCY BRABOIS   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d TIMONE HOSPITAL   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f HÔPITAL CIVIL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j Hôpital Guillaune et René Laënnec   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l HÔPITAL TENON   (France)

^m Milupa Nutricia France SA   (France)

ⁿ LOUIS PRADEL HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEMODYNAMICS; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCARDIOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; COMMUNICABLE DISEASES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK FACTORS; STEROIDS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 34347232669     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.05.002     Document Type: Article

References (19)

1. Koch A., Volker D., Dengler T.J., Schnabel P.A., Hagl S., and Sack F.U. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant 24 (2005) 708-713
2. Montoya J.G., Giraldo L.F., Efron B., et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 33 (2001) 629-640
3. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult transplant report-2003. J Heart Lung Transplant 22 (2003) 616-624
4. Smart F.W., Naftel D.C., Costanzo M.R., et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 15 (1996) 329-341
5. Faull R.J., Hollett P., and McDonald S.P. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 80 (2005) 193-197
6. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56 (2005) 71-85
7. Kahan B.D., Rajagopalan P.R., Hall M., and United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276-284
8. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327-1331
9. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24 (2005) 1297-1304
10. Delgado D.H., Miriuka S.G., Cusimano R.J., Feindel C., Rao V., and Ross H.J. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 24 (2005) 166-169
11. Hachem R.R., Chakinala M.M., Yusen R.D., et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 24 (2005) 1320-1326
12. Flaman F., Zieroth S., Rao V., Ross H., and Delgado D.H. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25 (2006) 1358-1362
13. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72 (2001) 1915-1919
14. Lebranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 (2002) 48-56
15. Mourad G., Rostaing L., Legendre C., Garrigue V., Thervet E., and Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584-590
16. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
17. Kobashigawa J.A., Renlund D.G., Gerosa G., et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 25 (2006) 935-941
18. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 325 (2005) 2705-2713
19. Kovarik J.M., Kahan B.D., Rajagopalan P.R., and The U.S. Simulect Renal Transplant Study Group. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation 68 (1999) 1288-1294